|
06 Sep 2025 |
Biocon
|
Consensus Share Price Target
|
363.70 |
380.11 |
- |
4.51 |
buy
|
|
|
|
|
13 Aug 2023
|
Biocon
|
ICICI Securities Limited
|
363.70
|
230.00
|
256.20
(41.96%)
|
Target met |
Sell
|
|
|
Biocon’s Q1FY24 performance was dragged by the biologics biz. Profitability of the segment was under pressure owing higher rebates in Fulphila (USD 15mn). Segmental PBT dropped 600bps QoQ to 1.6% in Q1FY24. US market share of Fulphila and Ogivri expanded by 200bps and 100bps QoQ to 16% and 11%, and stable at 12% for bGlargine.
|
|
29 May 2023
|
Biocon
|
Sharekhan
|
363.70
|
266.00
|
245.20
(48.33%)
|
Target met |
Hold
|
|
|
|
|
25 May 2023
|
Biocon
|
ICICI Securities Limited
|
363.70
|
250.00
|
243.00
(49.67%)
|
Target met |
Hold
|
|
|
Biocon Limited’s (Biocon) Q4FY23 performance was boosted by consolidation of the acquired business of biosimilars (segment revenue up 114% YoY) from Viatris. Reported gross margin was inflated by ~150bps and EBITDA margin by 360bps due to licensing income of Rs1.75bn.
|
|
25 May 2023
|
Biocon
|
Axis Direct
|
363.70
|
260.00
|
239.85
(51.64%)
|
Target met |
Hold
|
|
|
Current TP: Rs 260/share (Earlier TP: Rs 260/share)
|
|
25 May 2023
|
Biocon
|
ICICI Direct
|
363.70
|
235.00
|
239.85
(51.64%)
|
Target met |
Hold
|
|
|
|
|
24 May 2023
|
Biocon
|
Motilal Oswal
|
363.70
|
260.00
|
243.00
(49.67%)
|
Target met |
Neutral
|
|
|
|
|
09 Mar 2023
|
Biocon
|
Geojit BNP Paribas
|
363.70
|
238.00
|
223.85
(62.47%)
|
Target met |
Hold
|
|
|
|
|
20 Feb 2023
|
Biocon
|
AUM Capital
|
363.70
|
260.00
|
227.70
(59.73%)
|
Target met |
Neutral
|
|
|
|
|
16 Feb 2023
|
Biocon
|
Axis Direct
|
363.70
|
260.00
|
242.85
(49.76%)
|
Target met |
Hold
|
|
|
Recommendation: We maintain HOLD on the stock
|
|
16 Feb 2023
|
Biocon
|
ICICI Direct
|
363.70
|
230.00
|
242.85
(49.76%)
|
Target met |
Hold
|
|
|
|